Yet Another Blood Pressure Medication Added to Recall List

Comments (0)

Another blood pressure medication was added last week to the already-lengthy list of drugs that have been recalled because they contain valsartan. The recently added medications were made by Mylan Pharmaceuticals. They include valsartan, amlodipine/valsartan, and valsartan/hydrochlorothiazide tablets. They were distributed in the U.S. between March 2017 and November 2018.

The Food and Drug Administration has listed additional information about the specifics of the recall, including doses, expiration dates, and lot numbers, on its website. The recently-recalled drugs contain trances of N-nitroso-diethylamine (NDEA). NDEA has been classified as a carcinogen. Its is found in pollution, some drinking water, and certain foods.

The company is notifying its customers and arranging for the return of recalled products. These drugs are only the most recent recalls in a string of blood pressure medications that have been recalled due to cancer concerns. As with the other recalled blood pressure drugs, patients are advised to continue taking the tablets and to contact their doctors. The risk of harm to a patient’s health is considered to be higher if the treatment is stopped immediately without an alternative treatment than the risk of the patients continuing to take the recalled drugs.

This recall is only one of many that have occurred of prescription drugs this year. Unfortunately, many pharmaceutical companies produce drugs that are unsafe for consumption. When that occurs, if a patient is harmed as a result, the patient can be harmed as a result. If you have been harmed by a prescription drug, whether or not it has been recalled, you should speak with an attorney. Call the Houston prescription medication recall attorneys at 855-947-0707. We can help. Call today to learn more or to schedule a free consultation.

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.